PIQRAY

1.In case of severe hypersensitivity reactions- shortness of breath, skin rash, fever, itching then permanently discontinue Alpelisib and start appropriate treatment. 2.Severe skin reactions- In case of severe skin reactions like Stevens-Johnson syndrome (severe skin rash) and Erythema Multiforme (skin rash) discontinue Alpelisib and consult a dermatologist.‍‍‍‍‍‍​​​‍​​​​​​ Do not start treatment in patients with a history of Stevens-Johnson syndrome (SJS), Erythema Multiforme (EM) or Toxic Epidermal Necrolysis (TEN). 3.Before starting treatment with Alpelisib, test blood sugar parameters like fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After starting treatment with Alpelisib, monitor blood sugar levels and initiate appropriate medications. In case of severely high blood sugar levels, interrupt, stop or reduce the dose. 4.Alpelisib can cause severe pneumonitis (inflammation of lung tissue) and lung diseases. Monitor patients for the same and discontinue or interrupt the drug if severe pneumonitis occurs. 5.During treatment with Alpelisib, most patients experience diarrhea, start antidiarrheal treatment, increase oral fluid intake, and inform healthcare providers if diarrhea continues. If severe diarrhea occurs then interrupt, discontinue or reduce the dose of Alpelisib. 6.Embryo-fetal toxicity- Alpelisib can cause harm to the fetus. Males and females should use appropriate contraception during treatment and 1 week after treatment. 7.The patient should inform the healthcare provider about all the medicines they take including, OTCs, vitamins, herbal supplements, and prescription medicines.